A Study of DF6002 Alone and in Combination With Nivolumab
Completed · Phase 1 · NCT04423029
Conditions: Solid Tumors
At a glance
- Research payments reported, 2025
- $11,424
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 170
About the trial
- Sponsor
- Dragonfly Therapeutics
- Tested
- DF6002 (drug), Nivolumab (drug)
- Dates
- Started 2020-07-13; completion 2025-11-26
- Results posted
- Not yet
The purpose of this study is to evaluate the safety, tolerability, drug-levels, drug-effects and preliminary anti-tumor activity of DF6002 alone and in combination with Nivolumab in participants with advanced solid tumors.
From ClinicalTrials.gov, last updated 2026-03-18. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $11,424 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.